WTO director-general Lamy’s comments well recepted by GPhA
ARLINGTON, Va. Remarks by World Trade Organization director-general Pascal Lamy at the 11th annual International Generic Pharmaceutical Alliance conference in Geneva got a warm response from the Generic Pharmaceutical Association.
“The U.S. generic pharmaceutical industry has consistently argued that a sound balance needs to be struck between innovation and competition in a rules-based trading system,” GPhA president and chief executive officer Kathleen Jaeger said in a statement. “Director-general Lamy clearly affirmed that the GATT, the GATS and TRIPS all recognize the right of WTO members to give priority to health policies, even if it leads to trade restrictions.”
GATT, GATS and TRIPS refer respectively to the General Agreement on Tariffs and Trade, the General Agreement on Trade in Services and the Trade-Related Aspects of Intellectual Property Rights.
Lamy noted that the Paragraph 6 flexibilities relating to the 2001 Doha Declaration, often criticized as too cumbersome and complex, were used for the first time in September 2008 by Canada to ship HIV and AIDS medicines to patients in Rwanda. GPhA said the WTO should evaluate this in its next annual review so that it can enhance access to medicines.
Rite Aid upgrades cash registers to support FSA cards
CAMP HILL, Pa. Rite Aid has upgraded its pharmacy and front-end cash registers to make it easier for shoppers to use their Flexible Spending Account debit cards.
The pharmacy retailer is utilizing an inventory information approval system to allow customers to pay for eligible healthcare items with FSA debit cards. Eligible healthcare purchases on receipts are identified with an H to the right of the item’s price. These items are tallied by the cash register and can be paid for by an FSA debit card. The remaining balance for non-eligible items is paid for separately.
The FSA debits cards work similar to other debit cards and allow customers to buy certain health items using funds from a pre-tax accounts.
FDA delays approval of Remoxy painkiller
NEW YORK The Food and Drug Administration announced that it needed more clinical studies of the pain pill Remoxy before it would approve it.
The pill, a formulation of oxycodone by King Pharmaceuticals and Pain Therapeutics, is designed in a capsule form that prevents abuse by people trying to get high.
On Wednesday, King Pharmaceuticals’ shares were down by 83 cents, at $9.13, and Pain Therapeutics were down by $1.82, at $5.93.